A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, dose escalation study to assess the safety, tolerability, and
preliminary efficacy of SOT201 as monotherapy for participants aged 18 years or above with
advanced unresectable or metastatic solid tumors
During dose escalation, the recommended dose(s) of SOT201 given every 3 weeks (Q3W) will be
determined